A. Spatz

发表

Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.

Matthew R Groves, L. V. van Kempen, M. Groves, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene

D. Schadendorf, C. Greenwood, F. Pontén, 2016, Science Translational Medicine.

An experimental inter-expert telepathology network using static imaging.

G Brugal, G. Brugal, C. Busch, 2001, Journal of clinical pathology.

Biopsies: next-generation biospecimens for tailoring therapy

Sabine Tejpar, Caroline Rousseau, Gerald Batist, 2013, Nature Reviews Clinical Oncology.

A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens

C. Borchers, G. Batist, R. Zahedi, 2022, International journal of molecular sciences.

The dual role of the X‐linked FoxP3 gene in human cancers

L. V. van Kempen, A. Spatz, M. Redpath, 2011, Molecular oncology.

Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories

A. Karsan, M. Tsao, S. Kamel‐Reid, 2020 .

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.

A. Karsan, M. Tsao, S. Kamel‐Reid, 2018, Current oncology.

Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data

C. Borchers, G. Batist, R. Zahedi, 2019, Cancers.

Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)

C. Gilks, M. Tsao, C. Cheung, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma

H. Najafabadi, R. Alkallas, P. Lefrançois, 2020, Nature Cancer.

NEDD9 links anaplastic thyroid cancer stemness to chromosomal instability through integrated centrosome asymmetry and DNA sensing regulation

S. D. da Silva, M. Alaoui-Jamali, A. Spatz, 2022, Oncogene.

Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy.

L. Bégin, L. Salomon, F. Brimo, 2014, Human pathology.

The biology behind prognostic factors of cutaneous melanoma

G. Batist, A. Spatz, A. Eggermont, 2010, Current opinion in oncology.

TuBaFrost: European virtual tumor tissue banking.

P. Riegman, A. Llombart‐Bosch, P. Therasse, 2006, Advances in experimental medicine and biology.

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

A. Eggermont, A. Testori, J. Grob, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Do clinical criteria reflect pathologic complete response in rectal cancer following neoadjuvant therapy?

T. Vuong, A. Spatz, Livia Florianova, 2018, International Journal of Colorectal Disease.

Surgical Management for Prophylactic Oophorectomy in Women with an Inherited Risk of Ovarian Cancer

A. Chompret, P. Morice, S. Delaloge, 2001, Tumori.

BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells

M. Elchebly, E. Rubin, A. Papadakis, 2020, Cell death discovery.

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

D. Schadendorf, R. Dummer, A. Testori, 2012, European journal of cancer.

Laboratory-developed test for detection of acute Clostridium difficile infections with the capacity for quantitative sample normalization.

I. Brukner, A. Papadakis, V. Forgetta, 2019, Diagnostic microbiology and infectious disease.

Generalizability of Machine Learning Models: Quantitative Evaluation of Three Methodological Pitfalls

C. Reinhold, Rajiv Gupta, Farhad Maleki, 2022, Radiology. Artificial intelligence.

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

K. Bélanger, W. Miller, J. Cailhier, 2017, Journal of Immunotherapy for Cancer.

Canadian Multicentre Project on Standardization of PD-L1 22C3 Immunohistochemistry Laboratory Developed Tests for Pembrolizumab Therapy in Non-Small Cell Lung Cancer.

M. Tsao, C. Cheung, H. Sekhon, 2020, Journal of Thoracic Oncology.

The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.

L. Sakr, P. Fiset, A. Spatz, 2019, Lung cancer.

Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer

L. Sakr, P. Fiset, L. V. van Kempen, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

J. Blay, R. Schilsky, S. Ikeda, 2022, JCO precision oncology.

Direct and Precise Measurement of Bevacizumab Levels in Human Plasma Based on Controlled Methionine Oxidation and Multiple Reaction Monitoring.

Constance A. Sobsey, C. Borchers, R. Zahedi, 2020, ACS pharmacology & translational science.

Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection.

T. H. van der Kwast, P. Karakiewicz, T. Stockley, 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?

V. Lazar, C. Robert, A. Spatz, 2012, Current opinion in oncology.

Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients.

A. Eggermont, A. Testori, P. Patel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications.

A. Chompret, P. Morice, S. Delaloge, 2004, European journal of obstetrics, gynecology, and reproductive biology.

Phase II trial of perioperative chemotherapy + avelumab in locally advanced gastroesophageal adenocarcinoma: Preliminary results.

T. Alcindor, V. Marcus, L. Ferri, 2021 .

Human tissue research: EORTC recommendations on its practical consequences.

P. Therasse, W. Oosterhuis, I. Teodorović, 2003, European journal of cancer.

BORIS/CTCFL-mediated chromatin accessibility alterations promote a pro-invasive transcriptional signature in melanoma cells

M. Elchebly, E. Rubin, A. Papadakis, 2022, bioRxiv.

Borderline and malignant serous tumor arising in pelvic lymph nodes: evidence of origin in benign glandular inclusions.

R. Bentley, S. Robboy, P. Duvillard, 1995, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Nucleolar organizer regions in ovarian tumors: discrimination between carcinoma and borderline tumor.

P. Duvillard, P. Charpentier, A. Spatz, 1992, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Melanoma Group achievements

D. Schadendorf, M. Mihm, A. Eggermont, 2012 .

Molecular immuno‐imaging improves tumor detection in head and neck cancer

John W. Chen, G. Wojtkiewicz, Y. Iwamoto, 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Microcystic Adnexal Carcinoma: Report of Seven Cases Including One with Lung Metastasis

P. Petrow, P. Validire, M. Avril, 2006, Dermatology.

ATAC-Seq and RNA-Seq combined analysis elucidates the impact of BORIS/CTCFL on melanoma progression, mediated by chromatin accessibility and gene expression alterations

M. Elchebly, E. Rubin, A. Papadakis, 2022 .

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

D. Schadendorf, R. Dummer, A. Testori, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next Generation RNA Sequencing.

H. Feilotter, S. Yip, M. Tsao, 2022, The Journal of molecular diagnostics : JMD.

Cutaneous melanoma

A. Eggermont, C. Robert, A. Spatz, 2014, The Lancet.

A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110α in cell lines and tumor tissues.

Constance A. Sobsey, C. Borchers, G. Batist, 2021, The Analyst.

A Canadian guideline on the use of next-generation sequencing in oncology.

S. Banerji, G. Yousef, T. Stockley, 2019, Current oncology.

Spatially mapping the immune landscape of melanoma using imaging mass cytometry

H. Najafabadi, A. Mes-Masson, Luke Anderson-Trocmé, 2022, Science Immunology.

[Prostate cancer microenvironment: Its structure, functions and therapeutic applications].

F. Bladou, J. Irani, L. V. van Kempen, 2016, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

The validity of circulating microRNAs in oncology: Five years of challenges and contradictions

D. Schadendorf, C. Greenwood, L. V. van Kempen, 2014, Molecular oncology.

Integrating NGS-derived mutational profiling in the diagnosis of multiple lung adenocarcinomas.

J. Rivière, P. Broët, J. Spicer, 2021, Cancer treatment and research communications.

Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

Yannick-André Breton, C. Couture, G. Batist, 2020, Clinical Proteomics.

Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes

C. Couture, G. Batist, L. Tremblay, 2019, Molecular Cancer Therapeutics.

Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine

G. Batist, D. Bachvarov, B. Chabot, 2013, Modern Pathology.

EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer.

M. Tsao, S. Kamel‐Reid, A. Magliocco, 2012, Current oncology.

Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.

A. Karsan, Y. Yatabe, M. Tsao, 2021, Lung cancer.

Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer Cells

Constance A. Sobsey, C. Borchers, G. Batist, 2020, Proteomics. Clinical applications.

Canadian Perspective on the Clinical Management of Metastatic Melanoma

M. Smylie, A. Spatz, S. Ernst, 2012 .

TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network.

M M Morente, R Mager, S Alonso, 2006, European journal of cancer.

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.

A. Hauschild, J. Malvehy, H. Pehamberger, 2012, European journal of cancer.

Gene expression profiling of human angiotropic primary melanoma: selection of 15 differentially expressed genes potentially involved in extravascular migratory metastasis.

A. Eggermont, P. Dessen, V. Lazar, 2011, European journal of cancer.

Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies

W. Miller, G. Batist, M. Basik, 2011, Front. Pharmacol..

The role of molecular pathology in non-small-cell lung carcinoma-now and in the future.

A. Spatz, E. Brega, G. Brandão, 2012, Current oncology.

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)

L. Sakr, A. Papadakis, Hangjun Wang, 2022, Current oncology.

Importance of Adequate qPCR Controls in Infection Control

I. Brukner, A. Papadakis, A. Spatz, 2021, Diagnostics.

BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells

M. Elchebly, E. Rubin, A. Papadakis, 2019, Cell Death Discovery.

Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression

S. Michiels, V. Lazar, V. Winnepenninckx, 2012, Virchows Archiv.

Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment

P. Dupont, B. Dréno, F. Lehmann, 2008 .

Molecular pathology of cutaneous melanoma.

C. Robert, L. V. van Kempen, A. Spatz, 2014, Melanoma management.

Molecular testing in Cutaneous Melanoma

C. Robert, A. Spatz, M. Redpath, 2014 .

Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).

A. Eggermont, A. Testori, C. Punt, 2009, European journal of cancer.

EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.

D. Schadendorf, R. Dummer, M. Gore, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic and morphologic features for melanoma classification

D. Schadendorf, D. Elder, M. Mihm, 2010, Pigment cell & melanoma research.

EORTC Melanoma Group achievements

D. Schadendorf, M. Mihm, A. Eggermont, 2012 .

9302 Excellent long-term survival of patients with minimal sentinel node tumor burden (<0.1 mm) according to Rotterdam Criteria: a study of the EORTC melanoma group

H. Hoekstra, P. Rutkowski, A. Eggermont, 2009 .

D. Larsimont, G. Ghanem, A. Awada, 2013, British Journal of Cancer.

Melanoma — The pieces of the puzzle finally start coming together!

A. Spatz, A. Eggermont, 2011, Molecular oncology.

[Primary anorectal melanoma. Apropos of 19 cases].

S. Bonvalot, D. Elias, P. Lasser, 1997, Journal de chirurgie.

Reply to F. Janku et al

A. Bottomley, A. Eggermont, A. Testori, 2010 .

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

P. Ascierto, S. Aamdal, L. Bastholt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

A. Eggermont, A. Testori, C. Punt, 2013, Cancer Immunology, Immunotherapy.

Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care

B. Thombs, G. Batist, A. Körner, 2013, BMC Dermatology.

Absolute versus relative presentation of tcdB Clostridium difficile biomarker

I. Brukner, A. Papadakis, V. Forgetta, 2019, Integrative Molecular Medicine.

How iMALDI can improve clinical diagnostics.

R. Popp, M. Basik, A. Spatz, 2018, The Analyst.

TuBaFrost 3: regulatory and ethical issues on the exchange of residual tissue for research across Europe.

A. L. Bosch, P. Riegman, A. Carbone, 2006, European journal of cancer.

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?

T. Vuong, T. Alcindor, A. Spatz, 2012, British Journal of Cancer.

TuBaFrost 6: virtual microscopy in virtual tumour banking.

M M Morente, R Mager, S Alonso, 2006, European journal of cancer.

Next-generation sequencing of non-small cell lung cancer at a Quebec health care cancer centre.

J. Spicer, P. Fiset, L. Witkowski, 2023, Cancer treatment and research communications.

TuBaFrost 4: access rules and incentives for a European tumour bank.

M M Morente, K Knox, W N M Dinjens, 2006, European journal of cancer.

A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).

K. Bélanger, W. Miller, Shirin Kazemi, 2014 .

Leucocyte-derived micro-RNAs as candidate biomarkers in Brugada syndrome

Y. Bossé, I. Nault, N. Gaudreault, 2023, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

Yannick-André Breton, C. Couture, G. Batist, 2020, Clinical Proteomics.

Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning Models

B. O'Sullivan, C. Reinhold, G. Batist, 2021, Cancers.

P3.01-019 Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing

A. Karsan, M. Tsao, S. Kamel‐Reid, 2017 .

The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center

K. Sultanem, Hangjun Wang, A. Spatz, 2022, Current oncology.

Omics in melanoma - what have we learnt and what is the potential impact for patient management?

A. Eggermont, J. Oord, A. Spatz, 2007 .

Malignant melanoma and Kaposi's sarcoma: a possible additional syndrome to AIDS-related complex.

M. Avril, P. Duvillard, P. Charpentier, 1990, AIDS.